Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

The companies Kailera Therapeutics, Summit Therapeutics, and Tubulis bagged the biggest biotech funding rounds overall in ...

Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

A deficiency of dopamine: how does Parkinson’s disease affect the body? Unlike levodopa, which, when it reaches the brain gets converted to dopamine, the drug in question, tavapadon, activates ...

After decades of research, gut microbiome therapies are beginning to reach the market. Here are 11 of the companies harnessing the power of the microbiome to develop treatments derived from the gut.

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

The advent of CRISPR gene editing has enabled the creation of gene drives, a technology that can increase the odds of a certain gene being inherited. While the technology could help us tackle malaria ...

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC ...

The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as ...